Conference abstract · 20 Oct 2016
Conference abstractPublished 20 Oct 2016
Risk of cervical cancer associated with the coinfection of phylogenetically related genotypes and nonvaccine targeted HPV genotypes in Indian population
ICMR, Bhubaneswar, India; Acharya Harihara Regional Cancer Centre, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
HPV infection plays a central role in the development of cervical cancer. Among 184 different HPV genotypes, only 40 diverse types can infect anogenital region which can be classified into 3 classes based on their oncogenic potential. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 are included in high risk group while HPV6, 11, 40, 42, 43, 44, 54, 61, 70, 72 and 81 are in low risk group where as HPV 26, 53 and 66 belong to the group of intermediate risk. Cervical cancer is often associated with multiple HPV genotypes infection. Thus it is considered that co-infection may be a risk factor that drives carcinogenesis. But contradicting studies invoke confusion about the correlation between multiple infection and cervical disease. It is yet to be understood that whether the risk of cervical cancer is type specific or is it common for all the genotypes. This question is important for second generation vaccine strategy and disease management. With limited reports available, the present study aimed to investigate the risk conferred by specific hr-HPV genotypes co-infections towards invasive cervical carcinoma. 595 participants were enrolled for this study. Among them 346 were HPV positive. Among the HPV positive cases 172 were diagnosed with invasive cervical carcinoma and 174 were with normal cytology. A total of 346 samples were processed for HPV genotyping. E6/E7 multiplex nested type-specific PCR was done to detect 20 HPV genotypes. Association between the genotypes and cervical cancer was estimated by calculating the Odds ratio and 95% confidence interval. The most prevalent genotype was HPV 16 (87.28%) followed by HPV 18 (24.56%) and HPV 51 (3.46%). Other detected genotypes in descending order were HPV 39 (3.46%), HPV 66 (2.8%), HPV 68 (2.3%), HPV 35 (1.7%), HPV 45 (1.7%), HPV 44 (1.1%), HPV 58 (1.1%), HPV 52 (.57%), HPV 6/11 (.57%), HPV 42 (.57%) and HPV 43 (.57%). Prevalence of multiple genotypes was 23.41% with double, triple and quadruple genotypes while the prevalence of single genotype infection was 76.59%. Genotypes not targeted by quadrivalent vaccine types (OR=2.94 95% CI=1.48-5.80; p=.001) conferred a 2.94 fold risk of cervical carcinoma. Cases coinfected with phylogenetically related genotypes (OR=2.29; 95% CI=.69-7.59; p=.68) had 2.29 fold risk of cervical cancer. Genotypes not targeted by 9-valent vaccines (OR=.40; 95% CI=.19-.85; p=.017) conferred a lesser risk of cervical carcinoma. In conclusion, the risk of development of cervical cancer is genotype specific and might be associated with type-specific interactions between the genotypes in multiple infections.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 5 Sep 2011
HPV genotype in prognosis of Cervical Cancer
Conference abstract · 16 Oct 2017
Detection of Human Papillomavirus (HPV) genotypes and its association with p53 codon 72 polymorphism in prostate carcinomas
Conference abstract · 23 Nov 2012
Targeting transcription factor for treatment of HPV-Induced cervical cancer by herbal compounds
Conference abstract · 2018
High-risk HPV DNA genotyping for primary cervical cancer screening compared with cytology and colposcopy in HIV-positive women: preliminary results
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
How is really working adaptive immune system in mammals? A novel conception and reverse pathway theory, which will bring novel multibillion super-antibody (sab) technology for curing of all of infectious diseases and cancer!
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Rashmirani Senapati”
- BylineArticles whose byline prints “Bhagirathi Dwibedi”
- BylineArticles whose byline prints “Bhagyalaxmi Nayak”
- BylineArticles whose byline prints “Shantanu Kumar Kar”

